Sigma-2 Receptors Are Specifically Localized to Lipid Rafts in Rat Liver Membranes
Overview
Authors
Affiliations
We have previously shown that sigma-2 receptors are relatively difficult to solubilize (Eur. J. Pharmacol. 304 (1996) 201), suggesting possible localization in detergent-resistant lipid raft domains. Rat liver membranes were treated on ice with 1% Triton X-100 or 20 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), and the extract subjected to centrifugation on a discontinuous gradient of 5%, 38%, and 40% sucrose. Gradient fractions were analyzed for sigma-1 receptors using [3H]+-pentazocine and for sigma-2 receptors using [3H]1,3-di-o-tolylguanidine ([3H]DTG), in the presence of dextrallorphan. Flotillin-2 was assessed by immunoblotting as a marker for lipid rafts. Sigma-2 receptors were found to discretely co-localize with flotillin-2 in lipid raft fractions. However, sigma-1 receptors were found throughout the gradient. Rafts prepared in CHAPS had sigma-2 receptors with normal pharmacological characteristics, whereas those in Triton X-100-prepared rafts had about seven-fold lower affinity for [3H]DTG and other ligands. Thus, sigma-2 receptors are resident in membrane lipid rafts, whereas sigma-1 receptors appear in both raft and non-raft membrane domains. Lipid rafts may play an important role in the mechanism of sigma-2 receptor-induced apoptosis.
McDonald E, Pan T, Pant D, Troester M, Kossenkov A, Mankoff D Cancer Res Commun. 2025; 5(2):226-239.
PMID: 39804138 PMC: 11791746. DOI: 10.1158/2767-9764.CRC-23-0562.
Hong V, Rade A, Yan S, Bhaskara A, Yousuf M, Chen M eNeuro. 2024; 11(7).
PMID: 38866499 PMC: 11228697. DOI: 10.1523/ENEURO.0488-23.2024.
An Emerging Role for Sigma Receptor 1 in Personalized Treatment of Breast Cancer.
Robinson T, Osman M Cancers (Basel). 2023; 15(13).
PMID: 37444574 PMC: 10340381. DOI: 10.3390/cancers15133464.
Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders.
Malar D, Thitilertdecha P, Ruckvongacheep K, Brimson S, Tencomnao T, Brimson J CNS Drugs. 2023; 37(5):399-440.
PMID: 37166702 PMC: 10173947. DOI: 10.1007/s40263-023-01007-6.
Hough A, Criswell C, Faruk A, Cavanaugh J, Kolber B, Tidgewell K Mar Drugs. 2023; 21(2).
PMID: 36827151 PMC: 9966578. DOI: 10.3390/md21020110.